Article History
Accepted: 12 September 2019
First Online: 11 November 2019
Competing interests
: A.H. and B.W. are employees of and shareholders in Tango Therapeutics. L.A.G. is an employee of and shareholder in Eli Lilly and Company and is a shareholder in Tango Therapeutics. A.A. is a shareholder in Tango Therapeutics, a consultant for AtlasMDX, Third Rock Ventures, Pfizer, ProLynx and Bluestar and a Genentech scientific advisory board member and receives grant support from Sun Pharma and AstraZeneca. Patents on the use of PARP inhibitors held jointly with AstraZeneca that A.A. has benefited from financially (and may do so in the future) through the ICR Rewards to Inventors Scheme include WO2014013231 (A1) — 2014-01-23, US2012135983 (A1) — 2012-05-31, US2012010204 (A1) — 2012-01-12, US2006142231 (A1) — 2006-06-29, WO2008020180 (A2) — 2008-02-21.